VistaGen Therapeutics

VTGN71

Penny Stock

$2.66arrow_drop_down2.19%-$0.06

Penny Stock

VTGN71

$2.66

arrow_drop_down2.19%-$0.06

Penny Stock

Performance History

Key Stats
Open	$2.81
Prev. Close	$2.82
EPS	-0.93
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$78.73M
PE Ratio	-

	LOW	HIGH
Day Range	2.73	2.91
52 Week Range	2.45	5.86

Ratios







EPS	-0.93

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About VistaGen Therapeutics (VTGN)

VistaGen Therapeutics Inc (VTGN) is a biopharmaceutical company focused on developing innovative treatments to address unmet medical needs in the field of mental health. With a strong emphasis on utilizing cutting-edge stem cell technology, VistaGen is at the forefront of revolutionizing the way mental health disorders are diagnosed, treated, and managed. The company's vision is to provide patients with safer, more effective, and personalized therapies that can significantly improve their quality of life.

As of the latest market data, VistaGen Therapeutics Inc has a market capitalization of $XXX million. The company's stock, VTGN, has demonstrated a volatile trading history over the past year, with a 52-week range of $X.XX to $X.XX. The day range for VTGN currently stands at $X.XX to $X.XX. During recent trading sessions, the stock has seen notable trading volume, indicating increased investor interest.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Shawn K. Singh J.D.
Headquarters: South San Francisco
Employees: 32
Exchange: NASDAQ

Keep an eye on VistaGen Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is VistaGen Therapeutics 's (VTGN) price per share?

The current price per share for VistaGen Therapeutics (VTGN) is $2.66. The stock has seen a price change of -$0.06 recently, indicating a -2.2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for VistaGen Therapeutics (VTGN)?

For VistaGen Therapeutics (VTGN), the 52-week high is $5.86, which is 120.3% from the current price. The 52-week low is $2.45, the current price is 8.57% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is VistaGen Therapeutics (VTGN) a growth stock?

VistaGen Therapeutics (VTGN) has shown an average price growth of -4.94% over the past three years. It has received a score of 5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying VistaGen Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is VistaGen Therapeutics (VTGN) stock price performance year to date (YTD)?

As of the latest data, VistaGen Therapeutics (VTGN) has a year-to-date price change of -48.35%. Over the past month, the stock has experienced a price change of -11.92%. Over the last three months, the change has been -18.9%. Over the past six months, the figure is -41.15%. Looking at a longer horizon, the five-year price change stands at -70.44%.

help

Is VistaGen Therapeutics (VTGN) a profitable company?

VistaGen Therapeutics (VTGN) has a net income of -$29.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 46.62% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.77K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.06M, although specific revenue growth data is currently not available. The gross profit is $496K. Operating income is noted at -$33.02M. Furthermore, the EBITDA is -$45.47M.

help

What is the market capitalization of VistaGen Therapeutics (VTGN)?

VistaGen Therapeutics (VTGN) has a market capitalization of $73.86M. The average daily trading volume is 2.68, indicating the stock's liquidity and investor engagement.